[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112014016176A8 - sistema terapêutico transdérmico com uma baixa tendência de cristalização espontânea - Google Patents

sistema terapêutico transdérmico com uma baixa tendência de cristalização espontânea

Info

Publication number
BR112014016176A8
BR112014016176A8 BR112014016176A BR112014016176A BR112014016176A8 BR 112014016176 A8 BR112014016176 A8 BR 112014016176A8 BR 112014016176 A BR112014016176 A BR 112014016176A BR 112014016176 A BR112014016176 A BR 112014016176A BR 112014016176 A8 BR112014016176 A8 BR 112014016176A8
Authority
BR
Brazil
Prior art keywords
transdermal therapeutic
low tendency
spontaneous crystallization
therapeutic system
relates
Prior art date
Application number
BR112014016176A
Other languages
English (en)
Other versions
BR112014016176A2 (pt
BR112014016176B1 (pt
Inventor
Hoffmann Hans-Rainer
Dzekan Horst
Horstmann Michael
Wiedersberg Sandra
Müller Walter
Original Assignee
Lts Lohmann Therapie Systeme Ag
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47505017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014016176(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lts Lohmann Therapie Systeme Ag, Ucb Pharma Gmbh filed Critical Lts Lohmann Therapie Systeme Ag
Publication of BR112014016176A2 publication Critical patent/BR112014016176A2/pt
Publication of BR112014016176A8 publication Critical patent/BR112014016176A8/pt
Publication of BR112014016176B1 publication Critical patent/BR112014016176B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "sistema terapêutico transdérmico com uma baixa tendência de cristalização espontânea". a presente invenção refere-se aos sistemas terapêuticos transdérmicos para a dispensação de um produto farmacêutico, em particular um produto farmacêutico com uma baixa tendência de se cristalizar espontaneamente. a camada de matriz ou pelo menos uma das camadas de matriz em dito sistema contém um adesivo de fusão a quente de silicona, um produto farmacêutico, e partículas produzidas de polivinilpirrolidona reticulada. a invenção também se refere a um método para a produção de ditos sistemas terapêuticos transdérmicos.
BR112014016176-3A 2011-12-30 2012-12-28 Sistema terapêutico transdérmico com uma baixa tendência de cristalização espontânea e método para a formação do mesmo BR112014016176B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011090178.7 2011-12-30
DE102011090178A DE102011090178A1 (de) 2011-12-30 2011-12-30 Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
PCT/EP2012/077046 WO2013098390A1 (de) 2011-12-30 2012-12-28 Transdermales therapeutisches system mit geringer neigung zur spontankristallisation

Publications (3)

Publication Number Publication Date
BR112014016176A2 BR112014016176A2 (pt) 2017-06-13
BR112014016176A8 true BR112014016176A8 (pt) 2017-07-04
BR112014016176B1 BR112014016176B1 (pt) 2022-01-04

Family

ID=47505017

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016176-3A BR112014016176B1 (pt) 2011-12-30 2012-12-28 Sistema terapêutico transdérmico com uma baixa tendência de cristalização espontânea e método para a formação do mesmo

Country Status (10)

Country Link
US (2) US20140378917A1 (pt)
EP (1) EP2797588B1 (pt)
JP (1) JP6335790B2 (pt)
CN (2) CN110251490A (pt)
BR (1) BR112014016176B1 (pt)
CA (1) CA2861782C (pt)
DE (1) DE102011090178A1 (pt)
ES (1) ES2570205T3 (pt)
HK (1) HK1202430A1 (pt)
WO (1) WO2013098390A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU180500U1 (ru) * 2017-08-01 2018-06-14 Игорь Александрович Зябрев Технологическая головка для лазерной аддитивной технологии
US11607394B2 (en) 2017-12-19 2023-03-21 Hisamitsu Pharmaceutical Co., Inc. Rotigotine-containing patch
CN108358911A (zh) * 2018-04-19 2018-08-03 安徽德信佳生物医药有限公司 一种磁性诱导结晶分离东莨菪碱的方法
EP3925606A4 (en) 2019-02-15 2022-11-16 Hisamitsu Pharmaceutical Co., Inc. ROTIGOTINE STABILIZATION PROCESS
CN112891324A (zh) * 2021-01-19 2021-06-04 北京亚宝生物药业有限公司 一种透皮贴剂
CN117157062A (zh) * 2022-01-12 2023-12-01 新领医药技术(深圳)有限公司 抑制药物结晶的透皮贴剂及其制备方法
CN116829131B (zh) * 2022-01-12 2024-05-07 新领医药技术(深圳)有限公司 奥氮平透皮给药系统及其制备方法和用途
WO2023157865A1 (ja) 2022-02-21 2023-08-24 久光製薬株式会社 ロチゴチン含有貼付剤
KR20240141338A (ko) 2022-02-21 2024-09-26 히사미쓰 세이야꾸 가부시키가이샤 로티고틴 함유 첩부제
WO2024040860A1 (zh) * 2022-08-24 2024-02-29 新领医药技术(深圳)有限公司 抑制结晶的罗替高汀透皮给药系统及其制备方法和用途
WO2024145845A1 (zh) * 2023-01-04 2024-07-11 新领医药技术(深圳)有限公司 稳定的罗替高汀透皮给药试剂盒及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE3910543A1 (de) 1989-04-01 1990-10-11 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung
IT1243745B (it) 1990-10-17 1994-06-21 Vectorpharma Int Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione.
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
AU1120097A (en) 1995-12-01 1997-06-27 Alza Corporation Improved method for preventing crystal formation in a dispersion of a liquid in a matrix
US5663258A (en) * 1996-02-20 1997-09-02 Isp Investments Inc. Strongly swellable, moderately crosslinked copolymers of vinylpyrrolidone and vinyl acetate
JPH1045571A (ja) * 1996-07-29 1998-02-17 Sekisui Chem Co Ltd 貼付剤
JPH10306023A (ja) * 1997-05-06 1998-11-17 Sekisui Chem Co Ltd 経皮吸収製剤及びその製造方法
CA2302411C (en) * 1997-09-02 2007-01-30 Novartis Ag Improved method for preventing crystal formation in a scopolamine transdermal device
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
WO2000045797A1 (en) 1999-02-02 2000-08-10 Ortho-Mcneil Pharmaceutical, Inc. Method of manufacture for transdermal matrices
JP4428899B2 (ja) 1999-07-02 2010-03-10 エルテーエス ローマン テラピー−ジステーメ アーゲー ポリシロキサンおよび両親和性溶媒を基にした微小貯蔵所系
DE10012908B4 (de) 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
US6824874B1 (en) * 2000-08-23 2004-11-30 Dana Corporation Insulator and seal for fuel cell assemblies
EP1386605A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
EP1386604A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE102006026578B4 (de) * 2006-06-08 2009-01-08 Lts Lohmann Therapie-Systeme Ag Wirkstoffpartikelhaltiges Transdermales Therapeutisches System mit erhöhtem Wirkstofffluss und Verfahren zu seiner Herstellung sowie Verwendung
DE102006054732B4 (de) * 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
CN102281873A (zh) * 2008-10-06 2011-12-14 迈兰技术有限公司 非晶罗替戈汀（rotigotine）透皮系统
DE102009052972A1 (de) * 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
EP3257504B1 (en) 2009-12-22 2024-06-19 UCB Biopharma SRL Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
JP5766475B2 (ja) * 2010-03-30 2015-08-19 日東電工株式会社 貼付製剤およびその製造方法
SG187032A1 (en) * 2010-07-12 2013-02-28 Celgene Corp Romidepsin solid forms and uses thereof

Also Published As

Publication number Publication date
DE102011090178A1 (de) 2013-07-04
CN104144683A (zh) 2014-11-12
EP2797588B1 (de) 2016-04-27
ES2570205T3 (es) 2016-05-17
EP2797588A1 (de) 2014-11-05
JP2015503541A (ja) 2015-02-02
CA2861782C (en) 2020-04-14
US20140378917A1 (en) 2014-12-25
BR112014016176A2 (pt) 2017-06-13
CA2861782A1 (en) 2013-07-04
US20190328680A1 (en) 2019-10-31
JP6335790B2 (ja) 2018-05-30
CN110251490A (zh) 2019-09-20
BR112014016176B1 (pt) 2022-01-04
WO2013098390A1 (de) 2013-07-04
HK1202430A1 (zh) 2015-10-02

Similar Documents

Publication Publication Date Title
BR112014016176A2 (pt) sistema terapêutico transdérmico com uma baixa tendência de cristalização espontânea
BR112015021495A2 (pt) fabricação contínua integrada de substâncias de droga de proteína terapêutica
BR112012018075A2 (pt) "sistema e método de formação e dimensionamento de goma de mascar e/ou de alteração da temperatura da goma de mascar".
BR112014003919A2 (pt) métodos e meios para modificar um genoma de planta
BR112015005048A2 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
BR112013030894A2 (pt) moduladores do sistema imune
CU20140082A7 (es) Pirimidinas y triazinas fusionadas sustituidas y sus uso
ECSP14013224A (es) Pirimidinas anilladas sustituidas y uso de las mismas
CO7131375A2 (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CR20140321A (es) Sistema de administracion transdermica que contiene buprenofina
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
EP4400511A3 (en) Lipoprotein complexes and manufacturing and uses thereof
WO2013123215A3 (en) Antiviral drugs for treatment of arenavirus infection
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
BR112013022712A2 (pt) sistema e método de formar produto de confeitaria de múltiplas camadas
MX350875B (es) Formas de dosificacion farmaceutica de liberacion controlada.
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
CO6640246A2 (es) Forma cristalina del inhibidor sglt2 bencilbenceno
BR112015011389A2 (pt) Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica
BR112013033371A2 (pt) indicador de tempo-temperatura e um método de monitoração para a monitoração do estado de qualidade de um artigo termicamente sensível
WO2012174158A3 (en) Administration of benzodiazepine
BR112013004440A2 (pt) método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral
FR2977864B1 (fr) Procede de gestion de l'orientation de roues d'aeronef, notamment en cas d'eclatement ou degonflement de pneumatiques
BR112014021133A2 (pt) composto; composição farmacêutica; método para tratar, administrar e/ou reduzir as doenças ou distúrbios, síndrome ou afecções associados à modulação de receptor de captação de cálcio; e processo para a preparação de composto
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: LTS LOHMANN THERAPIE-SYSTEME AG (DE)